Bio-Hermes-002 is a collaborative study focused on new biomarkers designed to improve diagnosis of Alzheimer’s disease and dementias
Washington D.C., Oct. 14, 2026 – The Global Alzheimer’s Platform Foundation® (GAP) is pleased to welcome Niki BioSolutions, Inc. (NASDAQ: NIKI) and its wholly owned subsidiary, DiamiR Biosciences Corp. (DiamiR), to the Bio-Hermes-002 study. Bio-Hermes-002 is a unique observational platform study that evaluates blood-based and digital biomarkers across a wide spectrum of cognitive conditions, alongside MRI and PET imaging, in diverse racial and ethnic populations. It is designed to generate data that may improve the prediction, detection, and diagnosis of Alzheimer’s disease and related dementias.
The Bio-Hermes-002 study collects data reflecting the performance of each biomarker in the study, or combination of biomarkers, to assess, diagnose, or predict the presence of a variety of pathologies associated with Alzheimer’s disease and related dementias, including amyloid and tau in the brain, the hallmark characteristics of Alzheimer’s disease.
“DiamiR’s decision to join the growing list of collaborators in the Bio-Hermes-002 study adds essential genetic context to the blood, digital, and imaging biomarkers already collected,” said John Dwyer, President of GAP. “Bio-Hermes was designed to give the field data that will enhance the design and execution of Alzheimer’s clinical trials. Adding APOE genotyping makes Bio-Hermes an even more valuable resource.”
In Bio-Hermes-002, DiamiR is bringing genetic risk data to the study by performing apolipoprotein E (APOE) genotyping on plasma samples already collected from participants, augmenting our robust database and building upon findings from Bio-Hermes-001. DiamiR will use its New York State-approved, plasma-based APOE genotyping assay, which adds genetic information to banked samples without the need for additional blood draws.
“Bio-Hermes-002 is exactly the kind of program our laboratory was built to support,” said Alidad Mireskandari, Ph.D., MBA, President and Chief Operating Officer of Niki BioSolutions. “By delivering APOE genotyping directly from plasma, we can add genetic insight to existing biobanks at scale, an approach we believe has broad value for researchers and drug developers across the Alzheimer’s field.”
The APOE ?4 allele is the strongest known genetic risk factor for late-onset Alzheimer’s disease. APOE genotype informs clinical trial design and enrollment, as well as risk assessment for amyloid-related imaging abnormalities (ARIA) in people receiving anti-amyloid therapies. The resulting data will be integrated with the Bio-Hermes-002 dataset and may be made available to the research community, consistent with GAP’s data-sharing practices.
Niki BioSolutions joins a long list of industry leaders who are partners in this study, including Biogen, Eli Lilly and Company, IXICO, and Roche, along with other exceptional partners providing blood-based biomarker assessments or digital assessments for Bio-Hermes-002. To date, the partners include AINOSTICS, Alamar Biosciences, Beckman Coulter Diagnostics, Cambridge Cognition Limited, Cognivue, Cumulus Neuroscience Limited, Fujirebio, iLoF, LifeArc, Linus Health, Lucent Diagnostics–a Quanterix brand, Sanofi, Siemens Healthineers, Spear Bio, Taudia, and ViewMind.
For more information about the Bio-Hermes-002 study, visit https://globalalzplatform.org/.
About the Global Alzheimer’s Platform Foundation (GAP)
The Global Alzheimer’s Platform Foundation® (GAP) is dedicated to accelerating the delivery of treatments, therapies, and cures for people living with neurodegenerative diseases, like Alzheimer’s, Parkinson’s and Multiple Sclerosis. GAP works to lower costs and improve the efficacy of clinical trials and is committed to ensuring that no one is left behind. As part of its mission, GAP supports more than 75 clinical research sites worldwide through study start-up and recruitment activities, promotes diversity in research studies, and champions the citizen scientists who make research possible.
About Niki BioSolutions
Niki BioSolutions is a clinical-stage life sciences company focused on unmet medical needs and high-quality genomic and biomarker testing solutions to healthcare providers, research institutions, and life sciences organizations through its CLIA-certified, CAP-accredited laboratory. The company combines proprietary technologies with a commitment to scientific rigor to support precision medicine across a range of therapeutic areas, including neurodegeneration and other brain health conditions. Niki BioSolutions collaborates with leading academic centers, disease foundations, and biopharma companies.